Knock-out of ABCB1 in multidrug resistant osteosarcoma cell lines KHOSR2 and U-2OSR2 using CRISPR-Cas9 gene editing technology was able to restore doxorubicin sensitivity but had no effect on cisplatin sensitivity [315]. The gene discussed is ABCB1; the disease is osteosarcoma.